Trials / Conditions / Vaso-occlusive Crisis

Vaso-occlusive Crisis

28 registered clinical trials studyying Vaso-occlusive Crisis — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Outcomes of Vaso-occlusive Crisis in Pediatric Sickle Cell Disease NCT07200869	Assiut University	—
Not Yet Recruiting	Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric NCT06181695	Assistance Publique - Hôpitaux de Paris	Phase 3
Completed	Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease NCT06345638	University of Pennsylvania	—
Recruiting	Oral Ketamine for Treatment of Vaso-Occlusive Pain NCT05378555	Boston Children's Hospital	Phase 3
Unknown	Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Diseas NCT05289700	University Hospital, Geneva	Phase 3
Completed	Hyperbaric Oxygen Therapy in Sickle Cell Pain NCT03412045	University of Nebraska	N/A
Terminated	A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease NCT05348915	Pfizer	Phase 3
Terminated	A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Rec NCT04927247	Pfizer	Phase 3
Completed	A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing NCT04935879	Pfizer	Phase 3
Completed	Evaluation of Virtual Reality to Save Morphinic in the Treatment of Vaso-occlusive Seizures of Sickle Cell Pat NCT04756375	Assistance Publique - Hôpitaux de Paris	N/A
Terminated	Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in NCT04150757	Abigail Nixon	Phase 3
Completed	Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia NCT04301336	Beni-Suef University	Phase 2 / Phase 3
Unknown	Music Therapy in Sickle Cell Disease Vaso-occlusive Crisis NCT03639805	Assistance Publique - Hôpitaux de Paris	N/A
Recruiting	Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA) NCT05376046	BILLOIR	—
Recruiting	Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell NCT03353584	St. Jude Children's Research Hospital	N/A
Completed	Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis NCT03296345	UCSF Benioff Children's Hospital Oakland	Phase 2
Unknown	Validation of a Predictive Score of Acute Chest Syndrome NCT03032055	Soutien aux Actions contre les Maladies du Globule Rouge	—
Terminated	Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects NCT02433158	GlycoMimetics Incorporated	Phase 3
Terminated	Apixaban in Patients With Sickle Cell Disease NCT02179177	Nirmish Shah	Phase 3
Completed	Nitrous Oxide Analgesia Vaso-occlusive Crisis NCT01891812	Columbia University	Phase 2
Completed	Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) NCT01737814	Mast Therapeutics, Inc.	Phase 3
Terminated	A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. NCT01522196	Anthera Pharmaceuticals	Phase 2
Terminated	Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease NCT01501643	Assistance Publique - Hôpitaux de Paris	N/A
Completed	Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Hepa NCT01419977	Duke University	Phase 2
Completed	Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis NCT01119833	GlycoMimetics Incorporated	Phase 2
Withdrawn	Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlu NCT00711698	Johns Hopkins University	Phase 2
Completed	IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome NCT00434473	Anthera Pharmaceuticals	Phase 2
Terminated	Steroid Treatment for Sickle Cell Pain Crisis NCT00263562	Baylor College of Medicine	Phase 3